Abeona Therapeutics Inc./$ABEO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
- Ticker
- $ABEO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 226
- Headquarters
- Cleveland, United States
- Website
- www.abeonatherapeutics.com
ABEO Metrics
BasicAdvanced
$238M
-
-$1.18
1.34
-
Price and volume
Market cap
$238M
Beta
1.34
52-week high
$7.65
52-week low
$3.91
Average daily volume
1.1M
Financial strength
Current ratio
6.635
Quick ratio
6.318
Long term debt to equity
0.041
Total debt to equity
0.155
Interest coverage (TTM)
-25.25%
Profitability
EBITDA (TTM)
-80.789
Gross margin (TTM)
-39.90%
Net profit margin (TTM)
-246.42%
Operating margin (TTM)
-327.64%
Effective tax rate (TTM)
19.68%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-24.55%
Return on equity (TTM)
-43.13%
Valuation
Price to revenue (TTM)
9.116
Price to book
1.86
Price to tangible book (TTM)
1.86
Price to free cash flow (TTM)
-2.854
Free cash flow yield (TTM)
-35.04%
Free cash flow per share (TTM)
-1.461
Growth
Revenue change (TTM)
6,280.00%
Earnings per share change (TTM)
-219.53%
3-year revenue growth (CAGR)
92.67%
10-year revenue growth (CAGR)
38.98%
3-year earnings per share growth (CAGR)
-25.62%
10-year earnings per share growth (CAGR)
-22.86%
ABEO Financial Performance
Revenues and expenses
ABEO Earnings Performance
Company profitability
Upcoming events
No upcoming events
ABEO News
AllArticlesVideos
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
MarketBeat2 months ago
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
MarketBeat2 months ago
Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week
Benzinga2 months ago
Funds containing ABEO
Fund name | Fund size | $ABEO weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.